Clinical trial
An Observational Study of GIOTRIF (Afatinib) for First Line Therapy in Patients With Advanced Non Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR)-Mutations.
NCT02047903 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Observational Study of GIOTRIF (Afatinib) for First Line Therapy in Patients With Advanced Non Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR)-Mutations.
- Lead sponsor
- Boehringer Ingelheim
- Phase
- Observational
- Overall status
- Completed
- Start date
- March 5, 2014
- Completion date
- December 31, 2018
- Enrollment
- 161 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.